Researchers running the University of Oxford-led Com-COV study—launched earlier this year to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine—have today reported preliminary data revealing more frequent mild to moderate reactions in mixed schedules compared to standard schedules.